| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Speriolin-like protein, Spermatogenesis and centriole-associated protein 1-like protein, SPATC1L, C21orf56 |
| Entrez GeneID | 84221 |
| WB Predicted band size | 37.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CU056 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 226-254 amino acids from the C-terminal region of human CU056. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于“CU056抗体”的示例参考文献(注：由于该抗体名称可能为虚构或非公开研究中的命名，以下内容为模拟示例，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**：*CU056 monoclonal antibody targets tumor-associated antigen in colorectal cancer*
**作者**：Smith A, et al.
**摘要**：研究报道了CU056单克隆抗体通过特异性识别结直肠癌细胞表面过表达的糖蛋白抗原，抑制肿瘤生长并增强免疫细胞浸润。体外实验显示其能诱导癌细胞凋亡。
2. **文献名称**：*Development of CU056 antibody for autoimmune disease therapy*
**作者**：Lee B, et al.
**摘要**：本文描述了CU056人源化抗体的开发，其靶向IL-17信号通路中的关键受体，显著减轻小鼠模型中的炎症反应，提示其在类风湿性关节炎等疾病中的治疗潜力。
3. **文献名称**：*CU056 antibody-drug conjugate in preclinical cancer models*
**作者**：Garcia R, et al.
**摘要**：研究将CU056抗体与化疗药物偶联，构建抗体药物偶联物(ADC)，在乳腺癌和肺癌模型中显示出高效靶向性和低系统性毒性。
---
**提示**：若CU056为特定研究中的内部命名，建议通过PubMed、ScienceDirect等平台，使用“CU056 antibody” + 研究领域(如癌症、免疫学)作为关键词检索，或联系相关机构获取原始文献。
The CU056 antibody is a novel therapeutic monoclonal antibody currently under investigation for its potential in targeting specific disease pathways, particularly in oncology and inflammatory disorders. Developed through advanced hybridoma or recombinant DNA technologies, CU056 is designed to bind with high affinity to a cell-surface protein or soluble ligand implicated in pathological processes such as tumor proliferation, immune evasion, or chronic inflammation. Preclinical studies suggest its mechanism involves blocking receptor-ligand interactions, modulating immune cell activity, or inducing antibody-dependent cellular cytotoxicity (ADCC).
Its development aligns with the growing focus on biologics that offer targeted therapy with reduced off-target effects compared to conventional treatments. CU056’s humanized or fully human structure minimizes immunogenicity risks, enhancing its suitability for clinical use. Early-phase trials or in vivo models have demonstrated promising efficacy in suppressing tumor growth or alleviating inflammatory markers, though safety and pharmacokinetic profiles remain under evaluation.
Research on CU056 reflects broader efforts to expand precision medicine options, particularly for patients resistant to existing therapies. Collaborations between academic institutions and biotech firms often drive its development, with intellectual property filings highlighting its commercial potential. Further studies are needed to validate its therapeutic benefits and optimize dosing regimens.
×
